NIAID Locks Doors for Allergy Grant Gossip Session
Published Date: 3/19/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on April 28, 2025, to review and decide on grant applications for important clinical trial projects. This meeting affects researchers seeking funding for allergy and infectious disease studies, with no public access to protect privacy and trade secrets. The decisions made could impact future research funding and timelines.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Closed NIAID Grant Review Meeting
If you are a researcher who applied for NIAID clinical trial grants (including R34, R01, or U01 awards), your applications will be reviewed at a closed meeting on April 28, 2025, from 10:00 a.m. to 6:00 p.m. The meeting is closed to the public to protect confidential trade secrets and personal information, and the panel’s decisions could affect future research funding and project timelines.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17899, Proposed Collection; 60-Day Comment Request; Assurance (Interinstitutional, Foreign, and Domestic) and Annual Report (Office of the Director)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the Office of Laboratory Animal Welfare (OLAW) in the Office of Extramural Research (OER) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
Previous / Next Documents
Previous: 2025-04563, Request for Comments on the Reinstatement of a Previously Approved Collection: United States Marine Highway Program
MARAD wants to bring back a form that helps review grant applications for the United States Marine Highway Program. This program supports funding to grow and promote marine highway transportation, making shipping easier and greener. Changes in the law mean projects no longer need special approval before applying, so MARAD is asking for public feedback before restarting the process.
Next: 2025-04565, National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on April 18, 2025, to review important grant applications related to clinical trials and research projects. This meeting affects researchers seeking funding and keeps sensitive information private. It’s a key step in deciding who gets money to fight infectious diseases and allergies.